TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03485469

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypnosis
Description: There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
Study: NCT01913574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurolytic celiac plexus block (NCPB)
Description: An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
Study: NCT03289013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 1
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive 2
Description: This strip consists of a standard hydrocolloid adhesive found in ostomy devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-2
Description: Newly developed adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-21
Description: Newly developed adhesive
Study: NCT04818255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PET Biomarker Disclosure
Description: Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
Study: NCT03289013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-25
Description: Newly developed adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 33-20
Description: Newly developed adhesive
Study: NCT01700257

Intervention type: RADIATION
Group type: OTHER
Intervention: CT scan & Early CDT Lung test

Intervention type: OTHER
Group type: OTHER
Intervention: CT scan & Early CDT Lung test
Study: NCT04094116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ear wax syringing without pre ear oil treatment
Description: Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ear wax syringing without pre ear oil treatment
Description: Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
Study: NCT01533961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCYX-7158

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03252145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PhysioTouch
Description: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage (MLD)
Description: MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
Study: NCT03750877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median approach
Description: spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median approach
Description: spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian approach
Description: In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paramedian approach
Description: In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
Study: NCT03091738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon Pill
Description: Patients with compensated cirrhosis and insomnia will be provided ramelteon
Study: NCT03814902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Tracking Device
Description: This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
Study: NCT04019873

Intervention type: DRUG
Intervention: Dolutegravir (DTG)
Description: DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Dolutegravir (DTG)
Description: DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Dolutegravir (DTG)
Description: DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Lamivudine (3TC)
Description: 3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Lamivudine (3TC)
Description: 3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Lamivudine (3TC)
Description: 3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Rilpivirine (RPV)
Description: RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
Study: NCT00950729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving with running shoes
Description: Participant was asked to do all the experiments with their own running shoes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plaster cast
Description: The participant was ask to do all the experiments with a plaster cast molded on his right leg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving with Aircast
Description: The participant was ask to do all the experiments with a aircast on his right leg
Study: NCT03763201

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of GITR
Description: serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of GITR
Description: serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
Study: NCT02456025

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical tacrolimus
Description: Topical tacrolimus 0.01% twice daily for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tacrolimus
Description: Topical tacrolimus 0.01% twice daily for one month
Study: NCT00256932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Description: 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan
Description: 0.5 mg
Study: NCT04019873

Intervention type: DRUG
Intervention: Rilpivirine (RPV)
Description: RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.

Intervention type: DRUG
Intervention: Rilpivirine (RPV)
Description: RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
Study: NCT01521039

Intervention type: PROCEDURE
Intervention: Blood samples
Description: 2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
Study: NCT04464564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study: NCT00256932

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04240951

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat
Study: NCT04464564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study: NCT04240951

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat

Intervention type: OTHER
Group type: OTHER
Intervention: Sweat patch
Description: Flexible, epidermal, wearable skin patch to collect and analyze sweat
Study: NCT02748057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT01267929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The mirror neurons stimulation based VCD program
Description: The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The conventional physical therapy
Description: The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
Study: NCT03944863

Intervention type: DRUG
Intervention: Antibiotics
Study: NCT01341899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunosuppression and stem cell transplantation
Description: Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
Study: NCT01351207

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eggs
Description: Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eggs
Description: Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eggs
Description: Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
Study: NCT04808934

Intervention type: DRUG
Intervention: Apixaban
Description: Adults receiving apixaban

Intervention type: DRUG
Intervention: dabigatran
Description: Adults receiving dabigatran

Intervention type: DRUG
Intervention: rivaroxaban
Description: Adults receiving rivaroxaban

Intervention type: DRUG
Intervention: VKAs
Description: Adults receiving VKA
Study: NCT02719002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spectral domain optical coherence tomography C-scan and multifocal electroretinogram
Study: NCT04445090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03984214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol in Oral Dosage Form
Description: Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in Oral Dosage Form
Description: Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
Study: NCT02097511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate pretreatment
Description: Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate
Description: Sarpogrelate hydrochloride 100 mg three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Description: Sarpogrelate hydrochloride 100 mg three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol Tartrate 100 mg once a day
Study: NCT04149704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP video decision aid
Description: 10 minute video decision aid describing the goals-of-care options

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care-
Description: Verbal description of the three types of care
Study: NCT03744793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT04470453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be collected for measuring PG-MTX blood concentration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be collected for measuring PG-MTX blood concentration.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRQ
Description: Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRQ
Description: Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
Study: NCT02097511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol Tartrate 100 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol Tartrate 100 mg once a day
Study: NCT03101384

Intervention type: OTHER
Intervention: Diagnostic error
Description: There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
Study: NCT01649362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prefeeding oral stimulation program
Description: The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day.
Study: NCT02335879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gonal-F
Study: NCT04007510

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EPI-CAL data network
Description: This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Community DUP Assessment Tool
Description: A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
Study: NCT01763827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day
Study: NCT03127007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU based radio-chemotherapy
Description: IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU based radio-chemotherapy
Description: IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
Study: NCT04128683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromocriptine
Description: Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromocriptine
Description: Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
Study: NCT03915652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rheum iCMP
Description: Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rheum iCMP
Description: Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.